SPARC mRNA expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. This evidence concerns the gene SPARC and adenocarcinoma.